tolafentrine has been researched along with iloprost in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ghofrani, HA; Grimminger, F; Krupnik, E; Rose, F; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Walmrath, D; Weissmann, N | 1 |
Ghofrani, HA; Grimminger, F; Olschewski, H; Rose, F; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Weissmann, N; Wiedemann, R | 1 |
Ermert, L; Ghofrani, HA; Grimminger, F; Kreisselmeier, KP; Pullamsetti, S; Samidurai, A; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N | 1 |
1 trial(s) available for tolafentrine and iloprost
Article | Year |
---|---|
Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension.
Topics: Adult; Aerosols; Aged; Area Under Curve; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Naphthyridines; Phosphodiesterase Inhibitors; Statistics, Nonparametric; Vascular Resistance; Vasodilation; Vasodilator Agents | 2002 |
2 other study(ies) available for tolafentrine and iloprost
Article | Year |
---|---|
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemodynamics; Hypertension, Pulmonary; Iloprost; Naphthyridines; Pentoxifylline; Phosphodiesterase Inhibitors; Rabbits; Vasodilation; Vasodilator Agents | 2001 |
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gelatinases; Hemodynamics; Hypertension, Pulmonary; Hypertrophy; Hypertrophy, Right Ventricular; Iloprost; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocrotaline; Muscle, Smooth, Vascular; Naphthyridines; Oxygen; Phosphodiesterase Inhibitors; Pulmonary Artery; Pulmonary Gas Exchange; Pulmonary Heart Disease; Rats; Rats, Sprague-Dawley; Vasodilator Agents; Ventricular Remodeling | 2004 |